NASDAQ$SUPN
Supernus Pharmaceuticals Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Reported strong revenue and earnings performance despite generic entry of Trokendi XR.
Supernus Pharmaceuticals reported first quarter 2023 total revenues of $153.8 million, a slight increase compared to $152.5 million in the first quarter of 2022. Excluding Trokendi XR, net product sales increased by 25%. The company's GAAP operating earnings were $5.2 million, and non-GAAP operating earnings were $30.5 million. The company raised its full year 2023 GAAP and non-GAAP operating earnings guidance.
- Total revenues reached $153.8 million, compared to $152.5 million in Q1 2022.
- Qelbree net product sales were $25.8 million, a significant increase from $8.3 million in Q1 2022.
- GOCOVRI net product sales increased to $26.0 million, compared to $22.6 million in Q1 2022.
- GAAP operating earnings were $5.2 million, up from $2.0 million in Q1 2022.
Headline financials
Revenue & EPS history
Supernus · Revenue · Quarterly
$154M
Revenue by segment
Supernus · $63.7M total across 2 segments · Q1 2023
- Trokendi XR$34.8M-44.6%54.6%
- Oxtellar XR$28.9M+5.1%45.4%
Forward guidance
Supernus is increasing its prior financial guidance for GAAP operating loss and non-GAAP operating earnings, lowering financial guidance for combined R&D and SG&A expenses, and maintaining its financial guidance for total revenues for the full year 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2023
-0.5%
Avg return
Earnings day
+0.1%
Avg return
5 days after
+0.1%
Avg return
30 days after
48%
27 / 56 earnings
Positive
+22.3%
Q3 2020
Best reaction
-29.9%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.2% | +6.1% | -8.1% | |
| Q4 2025 | +7.9% | +0.7% | +0.1% | |
| Q3 2025 | -16.9% | -20.4% | -19.9% | |
| Q1 2025 | -4.6% | -0.9% | +2.2% | |
| Q4 2024 | -2.7% | -3.3% | -1.6% | |
| Q3 2024 | +2.3% | +7.7% | +9.4% | |
| Q2 2024 | +14.3% | +15.0% | +23.1% | |
| Q1 2024 | -3.7% | -4.7% | -15.7% | |
| Q4 2023 | +5.4% | +5.1% | +15.6% | |
| Q3 2023 | +9.6% | +14.5% | +12.8% | |
| Q2 2023 | -5.3% | -1.1% | -6.8% | |
| Q1 2023 | -0.2% | -7.2% | -3.3% | |
| Q4 2022 | +3.4% | +4.8% | -4.5% | |
| Q3 2022 | -5.9% | +0.9% | +2.5% | |
| Q2 2022 | +0.4% | -3.1% | +7.4% | |
| Q1 2022 | -6.0% | -2.5% | +2.7% | |
| Q4 2021 | -3.1% | -8.7% | -16.5% | |
| Q3 2021 | +5.0% | +11.6% | +1.1% | |
| Q2 2021 | -1.1% | -4.3% | +2.1% | |
| Q1 2021 | -2.7% | -2.5% | -0.7% | |
| Q4 2020 | -13.2% | -12.1% | -11.3% | |
| Q3 2020 | +22.3% | +28.4% | +18.5% | |
| Q2 2020 | -6.0% | -12.5% | -9.7% | |
| Q1 2020 | +4.7% | +4.3% | +7.8% | |
| Q4 2019 | -18.5% | -6.6% | -17.7% | |
| Q3 2019 | -29.9% | -23.6% | -22.8% | |
| Q2 2019 | -11.8% | -11.5% | -14.0% | |
| Q1 2019 | -7.0% | -5.0% | -20.3% | |
| Q4 2018 | +12.8% | +2.2% | -0.6% | |
| Q3 2018 | +8.4% | +8.6% | -2.8% | |
| Q2 2018 | -8.1% | -12.9% | -13.6% | |
| Q1 2018 | +6.3% | +26.5% | +20.2% | |
| Q4 2017 | +0.0% | +1.9% | +17.7% | |
| Q3 2017 | -13.4% | -11.4% | -13.3% | |
| Q2 2017 | +3.1% | +4.1% | +17.2% | |
| Q1 2017 | +0.0% | +4.2% | +28.7% | |
| Q4 2016 | -2.4% | -1.1% | +9.5% | |
| Q3 2016 | +5.1% | +10.2% | +11.1% | |
| Q2 2016 | +3.2% | +4.0% | -0.9% | |
| Q1 2016 | -5.7% | — | — | |
| Q4 2015 | +7.8% | — | — | |
| Q3 2015 | +6.0% | — | — | |
| Q2 2015 | -8.9% | — | — | |
| Q1 2015 | -7.1% | — | — | |
| Q4 2014 | +11.1% | — | — | |
| Q3 2014 | +4.1% | — | — | |
| Q2 2014 | +7.0% | — | — | |
| Q1 2014 | -3.7% | — | — | |
| Q4 2013 | +9.8% | — | — | |
| Q3 2013 | +9.5% | — | — | |
| Q2 2013 | +6.8% | — | — | |
| Q1 2013 | +10.0% | — | — | |
| Q4 2012 | -22.6% | — | — | |
| Q3 2012 | +2.8% | — | — | |
| Q2 2012 | -0.1% | — | — | |
| Q1 2012 | -5.9% | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro